Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging

Clinical Nuclear Medicine

Volumn 42, Issue 10, 2017, Pages 741-748

  Pandit Taskar, Neeta ^a   Zanzonico, Pat ^b   Hilden, Patrick ^c   Ostrovnaya, Irina ^c   Carrasquillo, Jorge A ^a   Modak, Shakeel ^d  

^a Molecular Imaging and Therapy Service   (United States)

^b Departments of Medical Physics   (United States)

^c Departments of Epidemiology and Biostatistics   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

123I MIBG; 131I MIBG; dosimetry; MIBG therapy; neuroblastoma; therapy planning

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; (3 IODOBENZYL)GUANIDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DOSIMETRY; DRUG MEGADOSE; FEMALE; HEART; HUMAN; HYPERBILIRUBINEMIA; LIVER; LUNG; LYMPHOCYTOPENIA; MALE; NEUROBLASTOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RADIOISOTOPE THERAPY; RADIOTHERAPY DOSAGE; RETREATMENT; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING; WHOLE BODY SCINTISCANNING; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; PROCEDURES; RADIATION DOSE; RADIOMETRY; RADIOTHERAPY PLANNING SYSTEM; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADULT; FEMALE; HUMANS; MALE; NEUROBLASTOMA; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOMETRY; RADIONUCLIDE IMAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 85028845596     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001752     Document Type: Article

References (22)

1. Brisse HJ McCarville MB Granata C. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011; 261: 243-257.
2. 123)I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 102: 1319-1326.
3. Monclair T Brodeur GM Ambros PF. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol. 2009; 27: 298-303.
4. Cohn SL Pearson AD London WB. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 2009; 27: 289-297.
5. 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014; 50: 801-815.
6. van Santen HM de Kraker J van Eck BL. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002; 94: 2081-2089.
7. Matthay KK Tan JC Villablanca JG. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006; 24: 500-506.
8. 131I-metaiodobenzylguanidine therapy: results of a phase II study. J Nucl Med. 2016; 57: 231-237.
9. 131I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012; 18: 2679-2686.
10. 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2011; 57: 1124-1129.
11. 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002; 29: 1581-1587.
12. Buckley SE Saran FH Gaze MN. Dosimetry for fractionated (131)I-MIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007; 22: 105-112.
13. Fielding SL Flower MA Ackery D. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991; 18: 308-316.
14. Lashford LS Lewis IJ Fielding SL. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992; 10: 1889-1896.
15. Matthay KK Panina C Huberty J. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001; 42: 1713-1721.
16. 131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012; 14: 735-742.
17. 131I]MIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015; 17: 284-294.
18. Brodeur GM Pritchard J Berthold F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 1466-1477.
19. Emami B Lyman J Brown A. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21: 109-122.
20. Stabin MG Sparks RB Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46: 1023-1027.
21. Grupp SA Cohn SL Wall D. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatr Blood Cancer. 2006; 46: 719-722.
22. 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009; 50: 1518-1524.